Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1440 - 1440

Published: Feb. 8, 2025

Antibody-based immune-stimulating drugs (ABIs) represent a transformative frontier in cancer immunotherapy, designed to reshape the tumor microenvironment and overcome immune suppression. This study highlighted recent advances ABIs, including antibody conjugates (ISACs), bispecific antibodies (BsAbs), checkpoint blockade enhancers, with focus on their mechanisms of action, clinical advancements, challenges. Preclinical findings revealed that ISACs effectively boost overall anti-cancer immunity by reprogramming tumor-associated macrophages, enhancing T cell activation, engaging other pathways. Similarly, BsAbs redirect cells tumors, achieving significant regression. Additionally, artificial intelligence (AI) is revolutionizing development ABIs optimizing drug design, identifying novel targets, accelerating preclinical validation, enabling personalized therapeutic strategies. Despite these challenges remain, resistance off-target effects. Future research should prioritize next-generation multifunctional antibodies, AI-driven innovations, combination therapies enhance efficacy expand applications. Connecting gaps could unlock full potential upgrading treatment improving outcomes for patients refractory or resistant tumors.

Language: Английский

Nanozyme-Based Strategies in Cancer Immunotherapy: Overcoming Resistance to Enhance Therapeutic Efficacy

Aging and Disease, Journal Year: 2025, Volume and Issue: unknown, P. 0 - 0

Published: Jan. 1, 2025

Nanozymes, which are nanomaterials that replicate the catalytic activities of natural enzymes in biological systems, have recently demonstrated considerable potential improving cancer immunotherapy by altering tumor microenvironment. Nanozyme-driven immune responses represent an innovative therapeutic modality with high effectiveness and minimal side effects. These nanozymes activate system to specifically recognize destroy cells. Combined immunotherapeutic agents, can amplify anti-cancer integrating remodeling immunogenic cell death (ICD). This review offers a thorough discussion about various involved immunity, including those mimicking catalase (CAT), superoxide dismutase (SOD), peroxidase (POD), oxidase (OXD). It also discusses challenges future directions for translating nanozyme platforms into clinical applications, enhancing susceptibility cells immunotherapy. Nanozyme-based strategies substantial oncology, offering new effective options management.

Language: Английский